PYXS Pyxis: Multiplikator nilai perusahaan marang pendapatan

Logo perusahaan publik Pyxis Oncology Inc. (PYXS)

The GURU.Markets terminal displays the change in EV/Sales valuation, where the 14610.51 metric serves as the target level. The environmental responsibility of Pyxis Oncology, Inc. (PYXS) is evident in its strict control of laboratory waste and energy conservation. A transparent ADC drug pipeline and management's expertise in pharmaceutical partnerships form the business foundation, while a high reputation within the oncology community confirms the potential of innovative targeted antibodies.

Nilai perusahaan marang pendapatan: Pyxis (PYXS) kanggo 23.11.2025 - 20.11.2026

Pyxis - rincian analitis lan metrik utama (PYXS)

- rega saham lan konsensus proyeksi valuasi:
Analisis wiwitan perusahaan:Pyxis Oncology Inc. PYXS
Sampel barang Pyxis Oncology Inc.

Analyzing the assets of Pyxis Oncology, Inc. (PYXS) requires an assessment of the market potential of its ADC platform. This enterprise value-to-revenue ratio measures the total value of the company, excluding debt, relative to its generated income. An increase in this metric signals inflated market expectations for targeted cancer therapy. An overly sharp spike in the multiple creates a risk of price correction, while stable dynamics confirm the fair capitalization of the biotech project.

Analisis pesaing Pyxis Oncology, Inc.

IBRX (immunitybio.com) - Rasio nilai perusahaan marang pendapatan|Immunocore Corp (IMCR) - Rasio nilai perusahaan marang pendapatan|Multiplikator nilai perusahaan marang pendapatan Janux Pharma (JANX)|Nilai perusahaan marang pendapatan RCUS|ZYME - Rasio nilai perusahaan marang dodolan|Nilai perusahaan marang pendapatan TNGX (Tango Pharma)|Koefisien nilai perusahaan marang pendapatan IOVA|Multiplikator EV/Sales IMTX (Immatics)|Nilai bisnis marang pendapatan XNCR|compasstherapeutics.com - Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan Replimune Inc.|Lyell Immunopharma (LYEL) - Rasio nilai perusahaan marang pendapatan|Innate Pharma S.A. - Nilai bisnis marang pendapatan|CGEN (Compugen Limited) - Multiplikator EV/Sales|Multiplikator EV/Sales IO Biotech Inc|Rasio nilai perusahaan marang pendapatan Sutro Biopharma (STRO)|INKT: Nilai perusahaan marang volume dodolan|Werewolf Therapeutics, Inc. - Nilai perusahaan marang pendapatan|Immix (IMMX) - Multiplikator nilai perusahaan marang pendapatan|ALX Oncology Holdings Inc. - Multiplikator EV/Sales|CUE - Multiplikator EV/Sales|PDSB: Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan Sonnet BioTherapeutics Holdings Inc. (SONN)|MAIA (MAIABiotech.com) - Multiplikator EV/Sales|Nilai perusahaan marang pendapatan Liminatus Pharma (LIMN)|Multiplikator EV/Sales LVTX|Koefisien nilai perusahaan marang pendapatan NXTC|Leap Therapeutics, Inc. - Nilai perusahaan marang pendapatan|INTS: Rasio nilai perusahaan marang pendapatan|Sensei Biotherapeutics Inc - Multiplikator EV/Sales|TOVX: Rasio nilai perusahaan marang pendapatan|gritstonebio.com (GRTS) - Rasio nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang pendapatan KA|Rasio nilai perusahaan marang pendapatan NexImmune, Inc.|Rasio nilai perusahaan marang pendapatan TSBX (Turnstone Biologics)|Nilai perusahaan marang pendapatan VCNX (Vaccinex, Inc.)|Koefisien nilai perusahaan marang pendapatan HARP